Navigation Links
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors

MENLO PARK, Calif., June 20 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) announced today that Christopher M. Smith and Arthur T. Taylor have been appointed to the company's board of directors.

"We expect to benefit greatly from the complementary skill sets that Chris and Art will add to our board of directors," said Gregory D. Casciaro, XTENT's President and CEO. "Both are medical device industry veterans whose experience and insight will be invaluable as we move toward commercialization of the Custom NX(R) Drug Eluting Stent System."

Smith is currently president of Cochlear Americas, a developer of implantable hearing devices. From October 2003 to August 2004, he was a consultant for Warburg Pincus, a private equity firm. From 2000 to 2003, Mr. Smith served as group president for Gyrus Group Plc, (a UK listed company), and as president and CEO-Director of Gyrus Medical. Smith, who currently serves on the board of a private company, received his B.S. in Journalism and Marketing from Texas A&M University.

Taylor served as a senior executive at Kyphon Products, Spinal & Biologics Business at Medtronic Inc. from November 2007 to May 2008. Prior to that, he was chief operating officer of Kyphon, a medical device company, from 2006 until the company's acquisition by Medtronic in November 2007, having served as chief financial officer of Kyphon from 2004 to 2006. Prior to joining Kyphon, he was senior vice president and chief financial officer of Terayon Communication Systems (subsequently acquired by Motorola), a broadband access and video processing technology company. Taylor holds a B.S. in Business Administration from San Diego State University and an M.B.A. from the University of Southern California.

Robert "Robin" Bellas of Morgenthaler Ventures, a founding venture capital investor in XTENT and a board member since 2002, will leave his board position this month as the new members assume their duties. "Robin's support and service to XTENT since our first days as a company have been invaluable. We are grateful for his guidance and contributions to our growth and maturation as a company," added Casciaro.


XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the size of the market for its products, the timing of the commercial launch of its products and the outcomes for treated patients. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's quarterly report on Form 10-Q for the quarter ended March 31, 2008. This quarterly report was filed with the SEC on May 13, 2008, and is available on the company's investor relations website at and on the SEC's website at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
2. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
3. XTENT Announces 2007 Financial Results
4. New study shows extent of harmful human influences on global ecosystems
5. XTENT Announces 2007 Financial Results Conference Call
6. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
7. XTENT Announces Third Quarter 2007 Financial Results
8. SAND Technology Appoints Zainab Ahmed Schwartz as CFO
9. Appoints New Chief Information Officer Laura Klein
10. Healthation CEO Appoints New Senior Vice President of Business Development
11. China Yingxia International, Inc. Appoints Chief Financial Officer
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... Khanna Vision Institute ... Board of Ophthalmology on November 25th 2015. Peer Certification by the Board is ... his specialty. Certification in Ophthalmology is first obtained after the completion of three years ...
(Date:11/29/2015)... IL (PRWEB) , ... November 29, 2015 , ... Effective ... In addition starting on Black Friday Target is offering a “Buy One ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on ... the COUCH BUDDY. "I conceived of this design due to personal experience with a ... users. It promotes relaxation and convenience, as well as increases support. It also makes ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
Breaking Medicine Technology: